4.6 Review

Efficiency of Diagnostic Testing for Helicobacter pylori Infections-A Systematic Review

期刊

ANTIBIOTICS-BASEL
卷 10, 期 1, 页码 -

出版社

MDPI
DOI: 10.3390/antibiotics10010055

关键词

Helicobacter pylori; diagnostic testing; antibiotics; systematic review; AMR

资金

  1. Innovative Medicines Initiative 2 Joint Undertaking [820755]
  2. European Union
  3. EFPIA
  4. bioMerieux SA
  5. Janssen Pharmaceutica NV
  6. Accelerate Diagnostics S.L.
  7. Abbott
  8. Bio-Rad Laboratories
  9. BD Switzerland Sarl
  10. Wellcome Trust Limited

向作者/读者索取更多资源

The study compared the costs and clinical effectiveness of diagnostic strategies for H. pylori infections and found testing to be the most cost-effective strategy in most cases. Some studies considered antimicrobial resistance (AMR) and found that incorporating AMR into the model may alter the efficiency of the testing strategy.
Background: The most recommended treatment for a Helicobacter pylori infection is high doses of combined antibiotics. The objective of this article is to perform a systematic review of the economic evaluation studies applied to assess the efficiency of diagnostic testing for H. pylori infections, so that their main characteristics can be identified and to learn from the literature how the antimicrobial resistance (AMR) issue is incorporated into these economic evaluations. Methods: We conducted a systematic review to compare the costs and clinical effectiveness of diagnostic strategies for H. pylori infections. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and extracted the items from the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. Results: We found thirteen articles that were of good quality according to CHEERS: six studies focused on diagnostics of Helicobacter pylori infections associated with dyspepsia and four on duodenal ulcers. Testing was found to be the most cost-effective strategy in eight articles. Four studies considered AMR. Conclusions: Testing was more cost-effective than empirical treatment, except in cases of high prevalence (as with developing countries) or when patients could be stratified according to their comorbidities. The introduction of AMR into the model may change the efficiency of the testing strategy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据